摘要
大量研究奠定了他汀类药物在心血管疾病一级和二级预防中不可动摇的地位.强化调脂的理念已经深入临床。大剂量他汀类药物治疗对肝脏和肌肉潜在的不良反应已得到医患的重视,而近年来对他汀类药物肾脏损害、神经系统不良反应、新发肿瘤和糖尿病等的担忧和争论始终没有停止。因此,
出处
《内科理论与实践》
2011年第6期416-420,共5页
Journal of Internal Medicine Concepts & Practice
参考文献10
-
1The Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian simvastatin survival study(4S)[J].Lancet,1994,344(8934):1383-1389.
-
2Bonovas S,Sitaras NM.Does pravastatin promote cancer in elderly patients? A meta-analysis[J].CMAJ,2007,176(5):649.
-
3McMurray JJ,Kjekshus J,Gullestad L,et al.Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure(CORONA)[J].Circulation,2009,120(22):2188-2196.
-
4Hsia J,MacFadyen JG,Monyak J,et al.Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin.The JUPITER trial(justification for the use of statins in prevention:an intervention trial evaluating rosuvastatin)[J].J Am Coll Cardiol,2011,57(16):1666-1675.
-
5Sharp Collaborative Group.Study of heart and renal protection(SHARP):randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438patients with chronic kidney disease[J].Am Heart J,2010,160(5):785-794,e10.
-
6The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID)Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med,1998,339(19):1349-1357.
-
7Streja L,Packard CJ,Shepherd J,et al.Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the west of scotland coronary prevention study(WOSCOPS)[J].Am J Cardiol,2002,90(7):731-736.
-
8Deedwania P,Stone PH,Bairey Merz CN,et al.Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease:results of the study assessing goals in the elderly (SAGE)[J].Circulation,2007,115(6):700-707.
-
9McKenney JM,Davidson MH,Jacobson TA,et al.Final conclusions and recommendations of the national lipid association statin safety assessment task force[J].Am J Cardiol,2006,97(8A):89C-94C.
-
10Heart Protection Study Collaborative Group.MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet,2002,360(9326):7-22.
同被引文献89
-
1杜瑞雪,叶平.2011年欧洲血脂异常管理指南解读[J].中国医学前沿杂志(电子版),2011,3(4):87-90. 被引量:9
-
2杨士杰,李栋,姜达.辛伐他汀对荷瘤小鼠抑瘤作用的实验研究[J].河北医药,2006,28(7):573-574. 被引量:3
-
3郭丽萍,罗建民.P21蛋白和生存素在美伐他汀诱导人非小细胞肺癌凋亡中的作用[J].解放军医学杂志,2006,31(9):873-875. 被引量:1
-
4中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5224
-
5Brass LM,Alberts M J, Sparks L. An assessment of statin safety by neurologists[ J ]. Am J Cardiol,2006,97 (8A) :86C - 88C.
-
6Sassano A, Platanias LC. Statins in tumor suppression[J]. Cancer Lett,2008,260(1 2) : 11-19.
-
7Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family ofdrugs as triggers of tumor-specific apoptosis[J]. Leukemia. 2002,16(4) : 508-519.
-
8Denoyelle C, Vasse M, K rner M, et al. Cerivastatin, an in- hibitor of HMCrCoA reductase, inhibits the signaling path- ways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study[J]. Carcinogenesis, 2001 ,22(8) : 1139-1148.
-
9HIGGINS JP, GREEN S. Cochrane Handbook for Systematic Reviews of Interventions VersionS. 0. 0 [updated February 2008][CP]. The Cochrane Collaboration,2008.
-
10Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis[J]. JAMA,2006,295(1):74-80.
引证文献5
-
1马秀敏.他汀类药物不良反应及防治措施[J].中国中医药咨讯,2012,4(1):376-376. 被引量:3
-
2孙春丽,吴锦晖.他汀类药物在老年人中的安全性[J].现代临床医学,2012,38(6):407-409.
-
3周俊翔,蒋刚.他汀类药物对肿瘤防治作用的临床证据评价[J].中国医院药学杂志,2014,34(15):1286-1291. 被引量:4
-
4刘海霞,李全斌.普伐他汀相关肌病不良反应的研究进展[J].实用药物与临床,2015,18(1):94-96.
-
5闫向勇,燕忠生.他汀类药物抗肿瘤作用研究进展[J].现代肿瘤医学,2017,25(12):2004-2007. 被引量:1
二级引证文献7
-
1黄丽花,赵思宁,劳可师.中药、西药和中西药结合三种方法降血脂作用及研究进展[J].右江民族医学院学报,2013,35(2):198-199. 被引量:7
-
2褚剑锋,吴广文,郑国华,郑峰,许剑锋,彭军,洪振丰.红景天治疗慢性稳定性心绞痛随机对照试验的系统评价[J].中国中西医结合杂志,2014,34(8):940-946. 被引量:13
-
3郑芳,赵金波.血脂水平与乳腺癌关系的研究进展[J].医学综述,2015,21(21):3913-3916. 被引量:10
-
4安鸣一.他汀类药物不良反应的研究进展[J].继续医学教育,2016,30(12):151-152. 被引量:1
-
5邹维,李卓,刚晓坤.脂代谢调节对老年前列腺癌患者治疗效果的影响[J].中国老年学杂志,2017,37(22):5631-5632. 被引量:1
-
6黄娜,王贝,魏明莉,张春露,李万成.阿托伐他汀对人肺腺癌细胞的凋亡作用及其调控机制研究[J].临床肺科杂志,2019,24(6):1079-1082. 被引量:2
-
7鲍双振,杨进强,王志超,赵风龙,尹长恒,邢宏利.阿托伐他汀早期干预绝经后乳腺癌患者的临床研究[J].河北医科大学学报,2020,41(8):915-918.
-
1杜贺,陈少萍.他汀类药物不良反应及相关因素的研究进展[J].中国心血管杂志,2014,19(6):463-466. 被引量:14
-
2方健.开创结核病治疗新纪元的链霉素[J].医食参考,2011(9):22-22. 被引量:1
-
3李学勋,李健,安毅.他汀类药物序贯疗法在急性冠状动脉综合征中应用的研究[J].医学综述,2013,19(4):690-693. 被引量:4
-
4田毅.瑞舒伐他汀强化调脂对不稳定型心绞痛患者氧化应激的影响[J].中国药师,2016,19(2):290-292. 被引量:10
-
5薛云.口服避孕药对狼疮患者是安全的[J].国外医学情报,2006,27(5):36-36.
-
6白延平,刘智娜,赵莉,陈俊民,高智耀,王晨霞.依折麦布联合氟伐他汀对冠心病高危患者的强化调脂作用[J].中国药业,2016,25(8):23-26. 被引量:8
-
7张秀平.慢性阻塞性肺病患者治疗中应用酒石酸美托洛尔的临床观察[J].山西医药杂志,2005,34(7):600-601.
-
8汪芳.纵览阿司匹林发展历史[J].中国全科医学,2016,19(26):3129-3135. 被引量:19
-
9梁春,吴宗贵.他汀类药物调脂治疗的昨天、今天和明天[J].上海医学,2005,28(4):270-273. 被引量:3
-
10叶平.他汀类药物安全性再认识[J].中华心血管病杂志,2013,41(7):540-541. 被引量:10